Human Immunodeficiency Virus

Partners-based HIV Treatment for Couples Attending Antenatal Care

Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Couples-based services
Sponsors:   Vanderbilt University Medical Center;   National Institute of Mental Health (NIMH)
Not yet recruiting - verified May 2017

Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk

Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Provision of multiple self-tests
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Mental Health (NIMH);   Impact Research & Development Organization;   RTI International
Not yet recruiting - verified May 2017

Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity

Condition:   HIV Infection
Intervention:   Other: Non interventional study
Sponsor:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting - verified September 2016

3BNC117 and 10-1074 in HIV Uninfected Adults

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: 3BNC117;   Drug: 10-1074;   Drug: Placebo
Sponsor:   Rockefeller University
Active, not recruiting - verified December 2016

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies

Condition:   Human Immunodeficiency Virus Type 1
Intervention:   Drug: Rilpivirine
Sponsor:   Janssen Sciences Ireland UC
Recruiting - verified May 2017

Factors Associated With Late HIV Diagnosis in Grampian: an Epidemiological Study

Condition:   Human Immunodeficiency Virus
Intervention:   Other: No intervention
Sponsors:   University of Aberdeen;   NHS Grampian
Completed - verified June 2016

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: Subjects do not receive study medication in this study 202094
Sponsors:   ViiV Healthcare;   Janssen, GlaxoSmithKline (GSK)
Active, not recruiting - verified April 2017

Regular HIV Testing Among At-Risk Latino Men

Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Behavioral: Social Network;   Behavioral: Comparison
Sponsors:   Medical College of Wisconsin;   National Institute of Mental Health (NIMH)
Enrolling by invitation - verified May 2016

Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)

Condition:   Human Immunodeficiency Virus
Interventions:   Behavioral: Cognitive-Based Compassion Training (CBCT);   Behavioral: Health discussion
Sponsor:   Emory University
Completed - verified January 2017

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART

Conditions:   Acquired Immunodeficiency Syndrome;   Human Immunodeficiency Virus Type
Sponsor:   Olayemi Osiyemi MD
Completed - verified October 2016

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Condition:   Human Immunodeficiency Virus Type 1
Interventions:   Drug: D/C/F/TAF;   Drug: Boosted Protease Inhibitor (bPI);   Drug: FTC/TDF
Sponsor:   Janssen R&D Ireland
Active, not recruiting - verified April 2017

The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV

Condition:   Human Immunodeficiency Virus Infection
Interventions:   Dietary Supplement: rice bran arabinoxylan compound (RBAC);   Dietary Supplement: Placebo
Sponsors:   University of Miami;   Daiwa Health Development
Completed - verified July 2016

Medication Adherence in Human Immunodeficiency Virus (HIV)

Condition:   Human Immunodeficiency Virus
Interventions:   Behavioral: Staff-delivered intervention sessions;   Other: Demographic Questionnaire;   Other: Questionnaires
Sponsor:   St. Jude Children's Research Hospital
Completed - verified July 2016

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: 744 Tablet;   Drug: 744 LA Injection;   Drug: Placebo Tablet;   Drug: Placebo Injection
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed - verified November 2016

HIV Non-Occupational Post-Exposure Prophylaxis

Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Sponsors:   Kenneth H. Mayer, MD;   Gilead Sciences
Completed - verified January 2017

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition:   Human Immunodeficiency Virus
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified March 2017

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Busulfan;   Biological: Cal-1 modified HSPC;   Biological: Cal-1 modified CD4+ T lymphocytes
Sponsor:   Calimmune, Inc.
Active, not recruiting - verified November 2016

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

Condition:   Human Immunodeficiency Virus
Interventions:   Device: Intervention Arm (computer-based CARE+ Corrections tool);   Other: Educational video on opiate overdose prevention
Sponsors:   George Washington University;   The Miriam Hospital;   New York University
Completed - verified December 2016

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

Condition:   HIV
Interventions:   Drug: antiretroviral therapy;   Behavioral: cell phone reminders;   Behavioral: contingency management for adherence
Sponsors:   UConn Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2016

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Active, not recruiting - verified May 2017

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: NRTIs;   Drug: Efavirenz
Sponsor:   Janssen-Cilag G.m.b.H
Completed - verified August 2016

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Condition:   Human Immunodeficiency Virus-1
Interventions:   Drug: BMS-663068;   Drug: BMS-663068;   Drug: BMS-663068;   Drug: BMS-663068;   Drug: Raltegravir;   Drug: Raltegravir;   Drug: Tenofovir;   Drug: Tenofovir;   Drug: Ritonavir;   Drug: Atazanavir
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified June 2016

HIV and Drug Use in Georgian Women

Condition:   Human Immunodeficiency Virus
Interventions:   Behavioral: RBT;   Other: Case-Management
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA)
Completed - verified August 2016

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition:   Human Immunodeficiency Virus (HIV)
Intervention:   Drug: Maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Active, not recruiting - verified December 2016

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

Condition:   Human Immunodeficiency Virus
Sponsors:   Johns Hopkins University;   National Institutes of Health (NIH)
Completed - verified August 2016

Refine Your Search Advanced Search